SCHEMBL374866

SCHEMBL374866

O=C1CC=Cc2sccc21

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.37
PTPRC P08575 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3797514 0.75
SCHEMBL3989392 0.69 CES1 (0.35) CES1PTPRC
SCHEMBL2818848 0.67 CES1 (0.37) CES1PTPRC
SCHEMBL3986724 0.65 CES1 (0.44) CES1PTPRC
SCHEMBL447698 0.63
SCHEMBL10536079 0.62 CES1 (0.41) CES1PTPRC
SCHEMBL20278752 0.62 PTP4A3 (0.42)
SCHEMBL9820301 0.61
SCHEMBL169947 0.61 CES1 (0.35) CES1PTPRC
SCHEMBL20366857 0.61 CDC25B (0.56) CES1PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120114459-A Application of benzofuranpyrimidinone or benzothiophene pyrimidinone compounds 南京工业大学 2025-06-10 CN claimed
CN-117800894-A Saturated cyclic derivative, pharmaceutical composition containing same and medical application of saturated cyclic derivative 苏州阿尔脉生物科技有限公司 2024-04-02 CN claimed
CN-115142281-B Dye micro-nanocrystallization method 安徽工程大学 2023-08-18 CN claimed
CN-114957282-A Near-infrared absorption organic small-molecule photovoltaic material based on benzothiophene/fluorine substituted benzothiophene derivative 东华理工大学 2022-08-30 CN claimed
US-20190169151-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2019-06-06 US claimed
EP-3442520-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2019-02-20 EP claimed
WO-2017180644-A1 THERAPEUTIC AURONES Middle Tennessee State University (US) 2017-10-19 WO claimed
EP-2680695-A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY Merck Sharp & Dohme Corp. (US) 2014-01-08 EP claimed
WO-2012118679-A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-07 WO claimed
EP-1877377-A2 PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES Wyeth (US) 2008-01-16 EP claimed
WO-2006118955-A2 PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES WYETH (US) 2006-11-09 WO claimed
US-20060247441-A1 Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles WYETH (US) 2006-11-02 US claimed
WO-1998034995-A1 COMPOUNDS AND METHODS FOR DOPING LIQUID CRYSTAL HOSTS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1998-08-13 WO claimed
JP-10087653-A None JP disclosed
CN-120349290-B Resist, preparation method, composition, adhesive layer and pattern forming method 南开大学 2026-05-19 CN disclosed
EP-4725941-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-15 EP disclosed
US-3972895-A ANIMAL GROWTH REGULATOR, HERBICIDE AMERICAN CYANAMID COMPANY (US) 1976-08-03 US disclosed
US-3953542-A CATALYST OF VANADIUM OR TITANIUM HALIDE, ALUMINUM TRIHYDROCARBON, AND A CARBONYL COMPOUND THE FIRESTONE TIRE & RUBBER COMPANY (US) 1976-04-27 US disclosed
US-3948869-A Process for polymerizing conjugated dienes THE FIRESTONE TIRE & RUBBER COMPANY (US) 1976-04-06 US disclosed
US-3944567-A ANIMAL GROWTH REGULATOR, HERBICIDE AMERICAN CYANAMID COMPANY (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247441-A1 Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles TPMT, TH, HTR3C CES1 3625/4885PTPRC 1352/4885
US-20190169151-A1 THERAPEUTIC AURONES AURKA, PIGS, PRF1 CES1 1169/4885PTPRC 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.